JAN Database Search Results

[Top page]

Search Keyword:Vedolizumab (Genetical Recombination)
Search Records:1

Vedolizumab (Genetical Recombination)

Vedolizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human α4β7 integrin monoclonal antibody and framework regions and constant regions derived from human IgG1, whose amino acid residues at positions 239 and 241 in the H-chains are substituted by Ala. Vedolizumab is produced in Chinese hamster ovary cells. Vedolizumab is a glycoprotein (molecular weight: ca. 150,000) composed of 2 H-chains (γ1-chains) consisting of 451 amino acid residues each and 2 L-chains (κ-chains) consisting of 219 amino acid residues each.


[Top page]
Contact Information for Japanese Accepted Names (JAN) Name and Structure Database
National Institute of Health Sciences